Key facts
- It has raised $21.8M; the latest was Later Stage VC ($6.9M) in Jan 2025.
- Notable investors include InterVest, STIC Ventures, Kiwoom Investment, SJ Investment Partners, AJU IB Investment — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Genkore
- ·The full record, as it builds
Funding rounds
No funding rounds for Genkore are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Genkore
Developer of a healthcare platform designed to provide gene therapy for medical emergencies. The company's platform offers healthcare educational programs such as genome editing technology, therapeutic approach, and plant biotechnology, enabling patients and the healthcare sector with a range of descriptions and information that improves the genetic status for health and welfare.
- Sector
- Healthcare
- HQ
- Daejeon, South Korea
- Founded
- 2019
- Employees
- 29
- Website
- genkore.com/
- Ownership
- Privately Held (backing)
Genkore doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Genkore shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Genkore in its N-PORT filings yet. We sweep new filings monthly.